clinical trial · NCT05518110
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
Cancer Trials Ireland·phase2·terminated·n = 20
Pancreatic CancerTrametinibHydroxychloroquine
brief summary
This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.
started
May 31, 2023
primary completion
Mar 3, 2026
completion
Mar 3, 2026
last updated
Apr 13, 2026
detailed description
The study is a multi-centre single arm Phase 2 clinical trial to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine. This study will include 10-22 patients with metastatic pancreatic cancer who have previously progressed on at least one line of systemic therapy.
official title
PaTcH Trial: A Phase 2 Study to Explore Primary and Emerging Resistance Mechanisms in Patients With Metastatic Refractory Pancreatic Cancer Treated With Trametinib and Hydroxychloroquine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol